Cancer clinical trials in the region Occitanie
174 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
Lung cancer
#NCT04995523
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
1
2
3 or more
Immunotherapy
5 main criterias to confirm
Centre Hospitalier Universitaire de Toulouse (Toulouse)
AstraZeneca
Phase 2
Lung cancer
#NCT04995523
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Immunotherapy
1
2
3 or more
5 main criterias to confirm
Centre Hospitalier Universitaire de Toulouse (Toulouse)
AstraZeneca
Phase 2
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
#NCT06162221
Locally Advanced
Metastatic
KRAS G12C
Systemic Treatment-Naive
Systemic Treatment-Naive
5 main criterias to confirm
IUCT Oncopôle (Toulouse)
Revolution Medicines, Inc.
Phase 2
Lymphoma
#NCT06271057
B cell lymphoma
Large B cell lymphoma
Primary mediastinal lymphoma
Indolent transformed lymphoma
> 60 ml/min
2
3 or more
Systemic Treatment-Naive
6 main criterias to confirm
IUCT Oncopôle (Toulouse), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier)
Organisation de recherche universitaire sur le lymphome
Phase 2
Liver and bile duct cancer
#NCT05622071
Hepatocellular carcinoma
Unhealthy
B
B
C
Transplant
Immunotherapy
7 main criterias to confirm
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
UNICANCER
Phase 2
Colon cancer
Rectal cancer
#NCT04956640
Locally Advanced
Metastatic
KRAS G12C
Chemotherapy
4 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Eli Lilly et compagnie
Phase 2
Pancreas cancer
#NCT04956640
Adenocarcinoma
Locally Advanced
Metastatic
KRAS G12C
4 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Eli Lilly et compagnie
Phase 2
Lymphoma
#NCT05283720
B cell lymphoma
Mantel cell lymphoma
CD20
None
1
2
3 or more
Bispecific T-cell engager antibodies
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2
Lymphoma
#NCT05283720
B cell lymphoma
Follicular lymphoma
CD20
1
2
3 or more
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2
Lymphoma
#NCT05283720
B cell lymphoma
Large B cell lymphoma
Indolent transformed lymphoma
CD20
None
1
2
3 or more
Bispecific T-cell engager antibodies
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Abbvie